Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | LDHA | P00338 | 2/20 | 0.40 |
| ▸ | LDHB | P07195 | 2/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16166767 | 0.90 | LMNA (0.39) | CSNK2A1MEN1KMT2ALDHALDHB | |
| SCHEMBL2669044 | 0.88 | LMNA (0.41) | KMT2ALDHALDHBALBNR1I2 | |
| SCHEMBL1107323 | 0.86 | ALDH1A1 (0.43) | LDHALDHBALBMAPTNR1I2 | |
| SCHEMBL2706652 | 0.84 | CA12 (0.41) | MEN1KMT2APTGS2CA12CA1 | |
| SCHEMBL1622103 | 0.84 | MYC (0.42) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL2642632 | 0.83 | PTGDR2 (0.42) | MEN1KMT2ACA1CA2CDK2 | |
| SCHEMBL2643375 | 0.83 | PTGDR2 (0.40) | KDM4CCA12CA1CA2CA9 | |
| SCHEMBL2642679 | 0.82 | HTT (0.50) | MEN1KMT2AKDM1AKDM4E | |
| SCHEMBL2643062 | 0.82 | MCL1 (0.47) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL2643501 | 0.81 | KDM4E (0.48) | KDM4CCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100348596-C | Indole-3-carboxamides as glucokinase (GK) activators | HOFFMANN LA ROCHE (CH) | 2007-11-14 | — | — | CN | disclosed |
| EP-1549638-B1 | INDOLE-3-CARBOXAMIDES AS GLUCOKINASE (GK) ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2007-10-03 | — | — | EP | disclosed |
| CN-1688574-A | Indole-3-carboxamides as glucokinase (GK) activators | HOFFMANN LA ROCHE (CH) | 2005-10-26 | — | — | CN | disclosed |
| EP-1549638-A1 | INDOLE-3-CARBOXAMIDES AS GLUCOKINASE (GK) ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-06 | — | — | EP | disclosed |
| US-6881844-B2 | Indole-3-carboxamides as glucokinase activators | HOFFMAN-LA ROCHE INC. (US) | 2005-04-19 | — | — | US | disclosed |
| WO-2004031179-A1 | INDOLE-3-CARBOXAMIDES AS GLUCOKINASE (GK) ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-15 | — | — | WO | disclosed |
| US-20040067939-A1 | Indole-3-carboxamides as glucokinase activators | CORBETT WENDY LEA (US) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067939-A1 | Indole-3-carboxamides as glucokinase activators | GCKR, GPR119, GCK | CSNK2A1 369/4885MEN1 3051/4885KMT2A 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.